DOI 10.1016/j.leukres.2025.107692
Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome.
Аннотация
OBJECTIVE
Therapies for patients with higher-risk myelodysplastic syndromes (HR-MDS) who have failed hypomethylating agents (HMAs) are needed. This Phase I/II study evaluates the safety, tolerability, and efficacy of venetoclax, an orally bioavailable BCL-2 inhibitor, in combination with azacitidine in this population.
METHODS
We conducted a single-center, dose-escalation, Phase I/II trial (NCT04550442) involving 33 patients with HR-MDS or CMML (IPSS ≥ 1.5) who had progressed after prior HMA therapy. Patients received intravenous or subcutaneous azacitidine (SC) (75 mg/m² for 5 days) and venetoclax (100-400 mg for 7-14 days in a 28-day cycle). The primary endpoints were safety/tolerability (Phase 1) and overall response rate (ORR) (Phase 2).
RESULTS
Patients received a median of 3 cycles (range, 1-22). The maximum tolerated dose of venetoclax was 400 mg. Common grade 3-4 adverse events included neutropenia (19 %) and thrombocytopenia (10 %). The 4-week early mortality rate was 9 %. The ORR was 49 %, and the median overall survival (OS) was 7 months (95 % CI, 3.5-10.5). The median progression-free survival (PFS) was 6 months (95 % CI, 3.0-9.0). Four patients (12 %) underwent stem cell transplantation, with 3 of 4 alive at last follow-up (75 %).
CONCLUSION
Combining venetoclax with azacitidine is feasible for HR-MDS and CMML patients who failed prior HMA therapy. However, this combination did not significantly improve clinical outcomes in this patient population.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.